Coagulation Analyzer Installation Acceptance Testing: A Practical Launch Checklist

A coagulation analyzer is not ready for patient testing simply because it powers on and produces a control result. Installation acceptance is the point at which the laboratory confirms that the instrument, reagents, software, environment, and local workflow operate together as intended. A disciplined acceptance process prevents unresolved setup issues from becoming routine reporting problems after launch.

The scope should match the analyzer and its intended test menu. A compact clotting instrument used for PT and APTT requires a different level of assessment from a high-throughput system combining clotting, chromogenic, and immunoturbidimetric assays. The underlying principle is the same: define what must work, collect objective evidence, resolve exceptions, and obtain laboratory approval before routine use.

Confirm the site before unpacking the instrument

Many installation problems begin outside the analyzer. The laboratory should confirm bench strength and clearance, ventilation, ambient temperature and humidity, electrical supply, grounding, network access, waste handling, water quality if required, and protection from direct sunlight or vibration. Reagent refrigeration and storage capacity should also be checked against the planned workload.

These conditions are easy to overlook when an installation is scheduled around delivery rather than site readiness. A pre-installation checklist shared among the laboratory, distributor, facilities team, and manufacturer reduces delays. It also establishes responsibility for items that cannot be corrected by the service engineer, such as unstable power, insufficient air conditioning, or missing network access.

Document the delivered configuration

Acceptance records should identify the analyzer model, serial number, software version, installed modules, computer and printer configuration, barcode functions, accessories, and supplied consumables. Shipping damage and missing components should be recorded before setup. The laboratory should retain installation reports and any baseline diagnostic results generated by the engineer.

Software version matters because calculation rules, flags, user permissions, reagent applications, and communication functions may change between releases. Configuration should reflect the ordered system rather than a generic factory profile. Date, time, language, units, decimal places, reportable ranges, alarm handling, and user access should be reviewed before analytical testing begins.

Install reagent applications as controlled methods

Each assay application combines reagent identity with volumes, incubation, detection settings, calibration model, measuring range, dilution rules, and result units. A PT, APTT, fibrinogen, thrombin time, D-Dimer, FDP, or antithrombin application should therefore be treated as a controlled method, not a menu label selected from software.

The laboratory and supplier should verify that the application matches the exact reagent format and analyzer model. Bottle type, dead volume, onboard position, mixing requirements, open-vial stability, and lot information should be included. If an OEM or localized reagent is used, the approved application version and change history should be clear. Unrecorded field adjustments may solve an immediate problem but create inconsistency across instruments and sites.

Check mechanical and fluidic performance

Service diagnostics provide an important baseline. Pipetting, probe alignment, liquid detection, reaction temperature, cuvette handling, optical or mechanical clot detection, washing, waste transfer, barcode reading, and sample transport should operate without unresolved errors. Background checks and blank measurements can help identify contamination, optical instability, or carryover before patient samples are introduced.

The engineer’s service checks do not replace laboratory observation. Operators should watch the complete workflow, including loading, aspiration, reagent mixing, reruns, dilution, reflex actions, result review, and shutdown. A process that passes diagnostics but is difficult to operate safely during peak workload still needs attention before go-live.

Establish calibration and quality control

Assays requiring calibration should be calibrated using the intended materials, lots, units, and application settings. The laboratory should review curve shape, replicate behavior, recovery, and any acceptance flags rather than accepting a software message alone. Calibration records should connect the analyzer, reagent lot, calibrator lot, application version, and date.

Quality-control testing should cover the levels relevant to each assay and demonstrate stable performance over multiple runs or days, according to the laboratory’s verification plan. New QC ranges may be needed for the local reagent-analyzer combination. A single acceptable control result is insufficient evidence of repeatability or operational stability. Staff should also confirm that QC rules, lockouts, comments, charts, and review permissions work as intended.

Compare results across the useful range

Patient-sample comparison helps show how the new analyzer or application relates to the current method. The sample set should cover normal and abnormal results and should include clinically important regions of the measuring range. For PT and APTT, both normal and prolonged samples are useful. For fibrinogen, D-Dimer, FDP, and antithrombin, low or cutoff-adjacent samples often provide more information than a set concentrated around common normal results.

Differences should be assessed against criteria defined before data review. A statistically visible difference is not automatically operationally important, and a high correlation does not rule out systematic bias. Unexpected results should trigger a structured review of sample quality, application settings, calibration, reagent handling, units, dilution, and comparison-method limitations.

Test carryover, limits, flags, and recovery paths

Acceptance should include the difficult parts of operation, not only routine samples. The laboratory should challenge high-to-low sample sequences where carryover is relevant, verify automatic dilution and rerun behavior, review results above and below analytical limits, and confirm that clot-curve or reaction flags are visible to operators. Manual recovery steps should be tested for sample shortage, reagent shortage, clots, probe errors, and interrupted runs.

These checks are particularly important when the instrument will operate overnight or with limited technical support. Staff need to know which problems they can resolve, which results require review, and when testing must stop. The distributor should provide escalation contacts and collect the diagnostic information needed for efficient remote support.

Verify the complete reporting chain

Laboratory information system testing should confirm patient identifiers, sample types, test codes, units, decimal places, reference intervals, flags, comments, corrected results, and bidirectional orders where used. The team should trace test orders from entry through analyzer processing to the final report. Manual entry and downtime procedures also need review because interface failure must not lead to uncontrolled transcription.

Reference intervals and decision limits should be appropriate for the local method and population requirements. The laboratory should not assume that values copied from a previous analyzer remain valid. PT-related reporting deserves special attention to calculation settings, local normal values, reagent characteristics, and any INR workflow used by the laboratory.

Close acceptance with training and ownership

Before launch, each operator should demonstrate routine startup, reagent loading, calibration or QC review, patient processing, flag interpretation, maintenance, troubleshooting, and shutdown. Training records should identify both the trainer and the assessed operator. Maintenance schedules, spare consumables, cleaning solutions, and first-line support responsibilities should be available at the bench.

The final acceptance record should list completed checks, open deviations, responsible persons, due dates, and formal approval for patient testing. Any unresolved issue that can affect result quality should be closed before launch. Lower-risk items may be tracked after go-live only when the laboratory has documented controls.

For laboratories, distributors, and IVD manufacturers, installation acceptance is a shared handover rather than a ceremonial signature. It turns delivered equipment into a controlled testing system. When site conditions, analyzer mechanics, reagent applications, calibration, QC, sample comparison, reporting, and staff competency are verified together, the laboratory begins routine work with evidence instead of assumptions.